News

UK report recommends better planning for phase I drug trials

BMJ 2007; 334 doi: 10.1136/bmj.39153.352234.DB (Published 15 March 2007)
Cite this as: BMJ 2007;334:551.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Susan Mayor
  1. London

    The first trials of new drugs in humans should be planned much more carefully, with the same clarity of purpose, design, and analysis as for studies supporting drug licensing, a report published this week recommends.

    The report, published by a working party of the Royal Statistical Society, was prompted by the TGN1412 drug trial last year in which six healthy volunteers experienced severe immune reactions (BMJ 2005;332:683, doi: 10.1136/bmj.332.7543.683). It found that “the trial design was not well suited to its objectives of testing the safety and tolerability of the drug.”

    Stephen Senn, professor of statistics at the University of Glasgow …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular